The association of paraoxonase 1 activities, serum mRNA expression and polymorphisms with in-stent coronary restenosis; a case-control study

PON1 polymorphisms and enzyme activity have been reported to be associated with cardiovascular disease (CVD). The aim of current study was to assess the association of these PON1 SNPs and serum enzyme activity and with restenosis following coronary artery stenting. A total of 306 unrelated Iranian patients with history of coronary stent implantation who underwent elective re-angiography were enrolled in the current study. Three single nucleotide polymorphisms (SNPs) of PON1 gene were genotyped. We used a double ARMS PCR method for genotyping at the Q192R and L55M loci, and PCR-RFLP method for C-108 T. Serum mRNA expression of PON1 was determined using SYBER green method and Roche LightCycler. There were 104 patients considered as in-stent restenosis (ISR) (mean age: 60.55 ± 8.60 years), and 202 individuals as non ISR (NISR) (mean age: 61.94 ± 9.18 years). There were no significant difference between paraoxonase and arylestrase actvities of paraoxonase 1 enzyme. Furthermore, there were no significant differences in the distribution of genotypes of PON1 polymorphism with ISR compared to the control group. The AAC haplotype was the most frequent haplotype in our population study, and haplotypes were not associated with ISR occurrence. The difference between serum mRNA expression of PON1 was not significant between ISR and NISR groups. According to our finding it seems that paraoxonase 1 activities, the most important polymorphisms of PON1 including Q192R, L55M and C-108 T and serum mRNA expression of PON1 are not beneficial markers for ISR diagnosis. •In-stent restenosis was not associated with PON1 polymorphisms.•In-stent restenosis was not associated with paraoxonase and arylestrase activities of paraoxonase 1 enzyme.•In-stent restenosis was not associated with PON1 serum mRNA expression.